Document is current

Any future updates will be listed below

Cutting-edge assays for mirabegron and tadalafil combo therapy for benign prostatic hyperplasia; insilico kinetics approach; multi trait sustainability assessment

Crossref DOI link: https://doi.org/10.1186/s13065-025-01497-z

Published Online: 2025-05-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark